OBI Pharma, Inc.

OBI Pharma, Inc.

Native name	台灣浩鼎生技股份有限公司
Company type	Public
Traded as	TWSE: 4174(TPEx)
Industry	Pharmaceuticals
Founded	2002
Headquarters	19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan
Key people	Kung-Yee Liang (Chairman)
Website	www.obipharma.com

OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.^[1][2]

In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).^[3]

History

The company was founded by Micheal N.Chang on April 29, 2002.^[4] It was formerly a subsidiary of Optimer Pharmaceuticals.

On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.

On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.

On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.

Primary Focus

The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.^[5]

References

• Optimer Pharmaceuticals

1. "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
2. "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
3. "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
4. "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
5. "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.